Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients
Table 5
Mortality rates of patients treated with (A) atorvastatin, (B) lovastatin, (C) pravastatin, (D) rosuvastatin, and (E) simvastatin, and matched control groups, and relative risk of death with 95% confidence interval and Benjamini-Hochberg adjusted p-value from the iteration with the least significant result for each comparison.